Arimoclomol for the Treatment of Niemann-Pick Disease Type C in a Real-World Setting: Long-Term Outcomes From an Expanded Access Program in the United States
Sunday, July 20, 2025 BiopharmaWatch Research 1 min read
Key Takeaway: The article discusses the long-term outcomes of Arimoclomol in treating Niemann-Pick Disease Type C through an expanded access program in the U.S. The findings indicate positive results, showcasing the treatment's effectiveness in a real-world setting. This research contributes valuable insights into the management of this rare disease.
Price reaction · baseline $12.07 (2025-07-18 close) · 1 other ZVRA headline(s) in the window, move may be shared
day 0 close · peak
-2.8%
Market Sentiment Analysis
POSITIVE FACTORS
Long-term outcomes from the expanded access program show promising results.
Arimoclomol demonstrates potential benefits for patients with Niemann-Pick Disease Type C.
The study highlights real-world effectiveness of the treatment.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+71%
120-day peak, hindsight
Typical move
10.7%
average across 6 past catalysts
Lead asset
KP415
Phase 3 · ADHD
Full Press Release Details
< Medical Publications and Presentations
Arimoclomol for the Treatment of Niemann-Pick Disease Type C in a Real-World Setting: Long-Term Outcomes From an Expanded Access Program in the United States
SERGG 2025 - 07/20/2025
Download PDF
Download PDF
Frequently Asked Questions
What is Arimoclomol used for?
Arimoclomol is used for treating Niemann-Pick Disease Type C.
What were the outcomes of the expanded access program?
The outcomes showed promising long-term results for patients.
Where was the expanded access program conducted?
The program was conducted in the United States.
What type of study was reported in the article?
The article reports on long-term outcomes from a real-world setting.